首页> 外文期刊>Transfusion medicine reviews >Comparison Between Standard and High Dose of G-CSF for Mobilization of Hematopoietic Progenitors Cells in Patients and Healthy Donors
【24h】

Comparison Between Standard and High Dose of G-CSF for Mobilization of Hematopoietic Progenitors Cells in Patients and Healthy Donors

机译:标准剂量和高剂量 G-CSF 动员患者和健康供体造血祖细胞的比较

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A standard dose of 10 pg/kg/day granulocyte colony stimulating factors (G-CSF) is currently recommended for hematopoietic progenitor cells (HPCs) mobilization. Our aim was to analyze whether certain patients or healthy donors could benefit from high dose of G-CSF.We performed a retrospective multicenter anal-ysis of HPCs mobilization procedures (2015-2020) in patients and healthy donors. Those who received standard dose of G-CSF (10 pg/Kg/day for 4 days to patients and healthy donors) and those that received higher dose (24 pg/Kg/day for 4 days to patients and 16 pg/Kg/day for 4 days to healthy donors) were compared.496 individuals were included (201 standard dose and 295 higher dose). Between standard or higher dose, we did not find significant differences in median number of mobilized CD34 + cells/mL, nei-ther among healthy donors (77 100 vs 75 500 respectively, P = .895), nor in patients (34 270 vs 33 704 respectively, P = .584). Additionally, among those with the same underlaying pathology the comparison between standard and higher dose did not showed differences. High G-CSF dose was not associated with a less frequent incidence of poor mobilizers ( < 20 0 0 0 CD34 + cells/mL) neither in healthy donors (1 1.3 vs 0; P = .218) nor patients (30 24.4 vs 32 18.1; P = .165). Multivariate analysis showed that age, gender, and G-CSF dose did not influence median number of mobilized CD34 + cells/mL in healthy donors or patients. However, the underlying pathology among patients significantly influenced the CD34 + cells mobilization. In healthy donors, cellular blood count showed significantly higher leukocytes and platelets count with G-CSF high-dose, while in patients just a higher platelets count was found. To conclude, high dose of G-CSF compared to standard dose did not show significant benefit in terms of mobilization of CD34 + cells in healthy donors or in patients, also without a decrease in the incidence of poor mobilizers.(c) 2022 Elsevier Inc. All rights reserved.
机译:目前推荐标准剂量为 10 pg/kg/天的粒细胞集落刺激因子 (G-CSF) 用于造血祖细胞 (HPC) 动员。我们的目的是分析某些患者或健康供体是否可以从高剂量的G-CSF中受益。我们在患者和健康供体中对 HPC 动员程序(2015-2020 年)进行了回顾性多中心分析。比较了接受标准剂量 G-CSF(患者和健康供体 10 pg/Kg/天,持续 4 天)和接受较高剂量(患者 24 pg/Kg/天,持续 4 天,健康供体 16 pg/Kg/天,持续 4 天)的患者,包括 496 人(201 人标准剂量和 295 人高剂量)。在标准剂量或更高剂量之间,我们没有发现健康供体(分别为77 100 vs 75 500,P = .895)和患者(分别为34 270 vs 33 704,P = .584)的动员CD34 +细胞/mL的中位数存在显著差异。此外,在具有相同基础病理学的患者中,标准剂量和较高剂量之间的比较没有显示出差异。在健康供体中,高 G-CSF 剂量与动员不良的发生率 ( < 20 0 0 0 CD34 + 细胞/mL ) 的发生率较低无关 (1 [1.3%] vs 0;P = .218) 和患者 (30 [24.4%] vs 32 [18.1%];P = .165)。多因素分析显示,年龄、性别和 G-CSF 剂量对健康供体或患者的动员 CD34 + 细胞/mL 的中位数没有影响。然而,患者的潜在病理学显着影响了CD34 +细胞的动员。在健康供体中,高剂量G-CSF组的细胞血细胞计数显示白细胞和血小板计数显著升高,而在患者中,仅发现较高的血小板计数。总而言之,与标准剂量相比,高剂量的G-CSF在健康供体或患者的CD34 +细胞动员方面没有显示出显着的益处,也没有降低动员不良的发生率。(c) 2022 年爱思唯尔公司保留所有权利。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号